STOCK TITAN

FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
FibroGen, Inc. (FGEN) to announce Q4 and full year 2023 financial results on February 26, 2024. Conference call scheduled to discuss corporate and financial performance.
Positive
  • None.
Negative
  • None.

SAN FRANCISCO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2023 financial results on Monday, February 26 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.

Conference Call and Audio Webcast
Interested parties may access a live audio webcast of the conference call via the “Investor Relations” page of the Company’s website at www.fibrogen.com. To access the call by phone, please go to this link (registration link), and you will be provided with dial-in details. To avoid delays, we encourage participants to dial in to the conference call fifteen minutes ahead of the scheduled start time. A replay of the webcast will also be available for a limited time at the following link (webcast replay).

About FibroGen  
FibroGen, Inc. is a biopharmaceutical company focused on accelerating the development of novel therapies at the frontiers of cancer biology. Pamrevlumab, an anti-CTGF fully human monoclonal antibody, is in clinical development for the treatment of metastatic pancreatic cancer and locally advanced unresectable pancreatic cancer (LAPC). Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. Roxadustat is in clinical development for chemotherapy-induced anemia (CIA) and a Supplemental New Drug Application (sNDA) has been accepted for review by the China Health Authority. FibroGen recently expanded its research and development portfolio to include antibody-drug conjugate (ADC) and immunoncology product candidates for the treatment of solid tumors. For more information, please visit www.fibrogen.com.

Contacts: FibroGen, Inc.

Investors:
David DeLucia, CFA
Vice President of Corporate FP&A / Investor Relations
InvestorRelations@fibrogen.com

Media:
Meichiel Keenan
Director, Investor Relations and Corporate Communications
media@fibrogen.com


FAQ

When will FibroGen announce its Q4 and full year 2023 financial results?

FibroGen will announce its Q4 and full year 2023 financial results on Monday, February 26, 2024, after the market close.

What time is the conference call scheduled for?

The conference call is scheduled for 5:00 PM Eastern Time on the same day as the financial results announcement.

How can interested parties access the conference call?

Interested parties can access a live audio webcast of the conference call via the 'Investor Relations' page of FibroGen's website at www.fibrogen.com.

Is there a replay of the webcast available?

Yes, a replay of the webcast will be available for a limited time at the provided webcast replay link.

FibroGen, Inc.

NASDAQ:FGEN

FGEN Rankings

FGEN Latest News

FGEN Stock Data

129.32M
82.99M
6.37%
71.45%
5.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAN FRANCISCO

About FGEN

fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. the company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (hif) biology to generate clinical programs targeting multiple therapeutic areas. fibrogen's most advanced product candidate, roxadustat (fg-4592), is an oral small molecule inhibitor of hif prolyl hydroxylases (hif-phs), in phase 3 clinical development for the treatment of anemia in chronic kidney disease (ckd). our second product candidate, fg-3019, is a monoclonal antibody in phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (ipf), pancreatic cancer and liver fibrosis. for more information please visit: www.fibrogen.com.